MBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
MUSTANG BIO, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$0.37−0.00 (-0.90%)
Close on Oct 19, 2026
- Market cap
- $2.51M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
7.1%
1M of 8M shares
Institutional holders
23
5 new, 3 sold out
Net institutional buying
0M
In Q2 2026
Insider trades, 12 months
1 buys · 2 sales
Net sold $4
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Fortress Biotech, Inc. | 537,243 | 8.00% | 13D (active) amendment | Jan 2, 2026 |
| Daniel B. Asher | 236,452 | 8.80% | 13G (passive) amendment | Mar 31, 2025 |
| Mitchell P. Kopin | 186,552 | 9.99% | 13G (passive) | Feb 5, 2025 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of MBIO | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Kestra Advisory Services, LLC | 196,991 | 2.60% | $138.29K | +20,949 | 0.00% |
| BlackRock, Inc. | 84,745 | 1.12% | $59.49K | – | 0.00% |
| Citadel Advisors LLC | 59,459 | 0.78% | $41.74K | +6,259 | 0.00% |
| Geode Capital Management, LLC | 42,240 | 0.56% | $29.65K | −50,550 | 0.00% |
| CFO4Life Group, LLC | 33,510 | 0.44% | $23.52K | +13,049 | 0.00% |
| Vanguard Fiduciary Trust Co | 32,120 | 0.42% | $22.55K | – | 0.00% |
| Vanguard Capital Management LLC | 25,704 | 0.34% | $18.04K | – | 0.00% |
| XTX Topco Ltd | 14,648 | 0.19% | $10.28K | New | 0.00% |
| Virtu Financial LLC | 14,356 | 0.19% | $10 | New | 0.00% |
| Two Sigma Securities, LLC | 13,742 | 0.18% | $9.65K | New | 0.00% |
| Susquehanna International Group, Llp | 13,664 | 0.18% | $9.59K | New | 0.00% |
| UBS Group AG | 4,155 | 0.05% | $2.92K | +496 | 0.00% |
| Tower Research Capital LLC (TRC) | 1,895 | 0.03% | $1.33K | – | 0.00% |
| Barclays PLC | 1,121 | 0.01% | $787 | New | 0.00% |
| SBI Securities Co., Ltd. | 509 | 0.01% | $357 | – | 0.00% |
| Morgan Stanley | 118 | 0.00% | $83 | – | 0.00% |
| Cullen/Frost Bankers, Inc. | 13 | 0.00% | $9 | – | 0.00% |
| Bnp Paribas Arbitrage, Snc | 6 | 0.00% | $4 | – | 0.00% |
| Nbc Securities, Inc. | 3 | 0.00% | $2 | – | 0.00% |
| JPMorgan Chase & Co | 2 | 0.00% | $1 | – | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 23 | 1M | 7.1% | 5 / 4 | 1 / 3 | 0M | 0M |
| Q1 2026 | 22 | 1M | 6.7% | 4 / 5 | 4 / 6 | 0M | 0M |
| Q4 2025 | 25 | 1M | 7.3% | 7 / 6 | 4 / 2 | 0M | 0M |
| Q3 2025 | 20 | 0M | 3.7% | 6 / 6 | 3 / 3 | 0M | 0M |
| Q2 2025 | 17 | 0M | 1.0% | 3 / 4 | 3 / 2 | 0M | 0M |
| Q1 2025 | 16 | 0M | 1.5% | 15 / 1 | 0 / 0 | 0M | 0M |
| Q4 2024 | 1 | 0M | 0.0% | 1 / 0 | 0 / 0 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of MBIO | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 84,144 | 1.11% | $56.38K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 25,704 | 0.34% | $18.04K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 4,184 | 0.06% | $2.80K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 1,077 | 0.01% | $722 | 0.00% | May 31, 2026 |
| Nomura Healthcare Fund | 160 | 0.00% | $112 | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Manuel Litchman MD | President, CEO and Interim CFO, Director | 1,615 | 0.02% | Apr 27, 2026 |
| Neil Herskowitz | Director | 145 | 0.00% | Dec 30, 2025 |
| Adam J. Chill | Director | 375 | 0.00% | Dec 30, 2025 |
| David Jin | Director | 286 | 0.00% | Dec 30, 2025 |
| Fortress Biotech, Inc. | 10% owner | 536,577 | 7.08% | Jan 5, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Manuel Litchman MD President, CEO and Interim CFO, Director | Apr 24, 2026 | Tax withholding | −19 | $0.75 | $14 | 1,615 |
| Fortress Biotech, Inc. 10% owner | Jan 2, 2026 | Award | +278,385 | – | – | 536,577 |
| David Jin Director | Dec 30, 2025 | Buy | +247 | $0.96 | $237 | 286 |
| Neil Herskowitz Director | Dec 30, 2025 | Sale | −247 | $0.96 | $237 | 145 |
| Adam J. Chill Director | Dec 30, 2025 | Sale | −4 | $0.95 | $4 | 375 |
| Fortress Biotech, Inc. 10% owner | Sep 29, 2025 | Award | +59,334 | – | – | 258,192 |
| Manuel Litchman MD President, CEO and Interim CFO, Director | Apr 24, 2025 | Tax withholding | −27 | $1.24 | $33 | 1,634 |
| Fortress Biotech, Inc. 10% owner | Mar 31, 2025 | Award | +67,806 | – | – | 198,858 |
| Fortress Biotech, Inc. 10% owner | Jun 27, 2024 | Award | +575,191 | – | – | 2,502,991 |
| Manuel Litchman MD President and CEO, Director | May 31, 2024 | Tax withholding | −1,396 | $0.35 | $489 | 83,024 |
| Fortress Biotech, Inc. 10% owner | Jan 2, 2024 | Award | +419,092 | – | – | 1,927,800 |
| Adam J. Chill Director | Jul 5, 2023 | Award | +7,246 | – | – | 19,170 |
| Neil Herskowitz Director | Jul 5, 2023 | Award | +7,246 | – | – | 19,703 |
| Lindsay A. Rosenwald Md Director | Jul 5, 2023 | Award | +7,246 | – | – | 60,525 |
| Michael S. Weiss Director | Jul 5, 2023 | Award | +7,246 | – | – | 49,637 |
| Michael J. Zelefsky Director | Jul 5, 2023 | Award | +7,246 | – | – | 18,970 |
| Manuel Litchman MD President and CEO, Director | Apr 24, 2023 | Tax withholding | −1,572 | $4.21 | $6.62K | 79,420 |
| Manuel Litchman MD President and CEO, Director | Apr 24, 2023 | Award | +5,000 | – | – | 111,079 |
| Fortress Biotech, Inc. 10% owner | Jan 6, 2023 | Award | +2,807,008 | – | – | 22,630,620 |
| Manuel Litchman MD Director | Sep 13, 2022 | Buy | +5,000 | $0.52 | $2.60K | 1,098,987 |
| Lindsay A. Rosenwald Md Director | Sep 13, 2022 | Buy | +5,000 | $0.52 | $2.60K | 299,181 |
| Michael J. Zelefsky Director | Jul 29, 2022 | Award | +71,664 | – | – | 175,861 |
| Adam J. Chill Director | Jul 29, 2022 | Award | +71,664 | – | – | 178,861 |
| Neil Herskowitz Director | Jul 29, 2022 | Award | +71,664 | – | – | 186,861 |
| Michael S. Weiss Director | Jul 29, 2022 | Award | +71,664 | – | – | 135,861 |
| Lindsay A. Rosenwald Md Director | Jul 29, 2022 | Award | +71,664 | – | – | 294,181 |
| Manuel Litchman MD Director | Jun 21, 2022 | Award | +61,000 | – | – | 1,093,987 |
| Manuel Litchman MD President and CEO, Director | Apr 24, 2022 | Tax withholding | −1,248 | $12.15 | $15.16K | 80,992 |
| Manuel Litchman MD Director | Mar 18, 2022 | Buy | +5,000 | $0.74 | $3.70K | 1,032,987 |
| Lindsay A. Rosenwald Md Director | Mar 18, 2022 | Buy | +4,094 | $0.74 | $3.03K | 222,517 |
| Brian Achenbach SVP, Fin. & Corp. Controller | Dec 14, 2021 | Sale | −4,374 | $1.83 | $8.00K | 144,729 |
| Brian Achenbach SVP, Fin. & Corp. Controller | Dec 8, 2021 | Award | +22,500 | – | – | 149,103 |
| Manuel Litchman MD President and CEO, Director | Oct 27, 2021 | Buy | +65,000 | $2.24 | $145.60K | 1,027,987 |
| Brian Achenbach SVP, Fin. & Corp. Controller | Oct 12, 2021 | Sale | −4,450 | $2.28 | $10.15K | 126,603 |
| Lindsay A. Rosenwald Md Director | Aug 31, 2021 | Award | +1,170 | $2.58 | $3.02K | 218,423 |
| Manuel Litchman MD President and CEO, Director | Aug 31, 2021 | Award | +2,746 | $2.58 | $7.08K | 962,987 |
| Manuel Litchman MD President and CEO, Director | Jul 30, 2021 | Buy | +86,206 | $2.91 | $250.86K | 960,241 |
| Michael S. Weiss Director | Jun 28, 2021 | Award | +13,774 | – | – | 64,197 |
| Lindsay A. Rosenwald Md Director | Jun 28, 2021 | Award | +13,774 | – | – | 217,253 |
| Neil Herskowitz Director | Jun 28, 2021 | Award | +13,774 | – | – | 115,197 |
| Adam J. Chill Director | Jun 28, 2021 | Award | +13,774 | – | – | 107,197 |
| Michael J. Zelefsky Director | Jun 28, 2021 | Award | +13,774 | – | – | 104,197 |
| Manuel Litchman MD President and CEO, Director | Jun 17, 2021 | Award | +61,000 | – | – | 874,035 |
| Brian Achenbach SVP, Fin. & Corp. Controller | Apr 9, 2021 | Sale | −2,423 | $3.36 | $8.14K | 131,053 |
| Manuel Litchman MD President and CEO, Director | Mar 5, 2021 | Buy | +165,562 | $3.12 | $516.55K | 825,408 |
| Manuel Litchman MD President and CEO, Director | Feb 26, 2021 | Award | +5,000 | $2.83 | $14.15K | 659,846 |
| Lindsay A. Rosenwald Md Director | Feb 26, 2021 | Award | +1,043 | $2.83 | $2.95K | 203,479 |
| Brian Achenbach SVP, Fin. & Corp. Controller | Dec 15, 2020 | Award | +22,500 | – | – | 151,774 |
| Manuel Litchman MD President and CEO, Director | Dec 15, 2020 | Buy | +100,000 | $2.91 | $291.00K | 654,846 |
| Lindsay A. Rosenwald Md Director | Dec 14, 2020 | Buy | +100,000 | $2.66 | $266.00K | 202,436 |
| Lindsay A. Rosenwald Md Director | Dec 14, 2020 | Buy | +100,000 | $2.66 | $266.00K | 200,423 |
| Brian Achenbach SVP, Fin. & Corp. Controller | Dec 8, 2020 | Sale | −5,185 | $3.03 | $15.71K | 133,476 |
| Brian Achenbach SVP, Fin. & Corp. Controller | Oct 21, 2020 | Sale | −3,056 | $2.97 | $9.08K | 138,661 |
| Manuel Litchman MD President and CEO, Director | Sep 15, 2020 | Award | +61,000 | – | – | 554,846 |
| Lindsay A. Rosenwald Md Director | Aug 31, 2020 | Award | +1,182 | $2.48 | $2.93K | 102,436 |
| Manuel Litchman MD President and CEO, Director | Aug 31, 2020 | Award | +5,000 | $2.48 | $12.40K | 493,846 |
| Lindsay A. Rosenwald Md Director | Jul 14, 2020 | Award | +16,611 | $2.48 | $41.20K | 101,254 |
| Neil Herskowitz Director | Jul 14, 2020 | Award | +16,611 | – | – | 101,423 |
| Lindsay A. Rosenwald Md Director | Jul 14, 2020 | Award | +16,611 | – | – | 100,423 |
| Adam J. Chill Director | Jul 14, 2020 | Award | +16,611 | – | – | 93,423 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.